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Abstract
Background: Accumulating evidence suggests glucagon-like peptide-1 (GLP-1) exerts cardioprotective effects in
animal models of myocardial infarction (MI). We hypothesized that chronic treatment with GLP-1 or the exenatide
analog AC3174 would improve cardiac function, cardiac remodeling, insulin sensitivity, and exercise capacity (EC) in
rats with MI-induced chronic heart failure (CHF) caused by coronary artery ligation.
Methods: Two weeks post-MI, male Sprague-Dawley rats were treated with GLP-1 (2.5 or 25 pmol/kg/min), AC3174
(1.7 or 5 pmol/kg/min) or vehicle via subcutaneous infusion for 11 weeks. Cardiac function and morphology were
assessed by echocardiography during treatment. Metabolic, hemodynamic, exercise-capacity, and body
composition measurements were made at study end.
Results: Compared with vehicle-treated rats with CHF, GLP-1 or AC3174 significantly improved cardiac function,
including left ventricular (LV) ejection fraction, and end diastolic pressure. Cardiac dimensions also improved as
evidenced by reduced LV end diastolic and systolic volumes and reduced left atrial volume. Vehicle-treated CHF
rats exhibited fasting hyperglycemia and hyperinsulinemia. In contrast, GLP-1 or AC3174 normalized fasting plasma
insulin and glucose levels. GLP-1 or AC3174 also significantly reduced body fat and fluid mass and improved
exercise capacity and respiratory efficiency. Four of 16 vehicle control CHF rats died during the study compared
with 1 of 44 rats treated with GLP-1 or AC3174. The cellular mechanism by which GLP-1 or AC3174 exert
cardioprotective effects appears unrelated to changes in GLUT1 or GLUT4 translocation or expression.
Conclusions: Chronic treatment with either GLP-1 or AC3174 showed promising cardioprotective effects in a rat
model of CHF. Hence, GLP-1 receptor agonists may represent a novel approach for the treatment of patients with
CHF or cardiovascular disease associated with type 2 diabetes.
Introduction
Glucagon-like peptide-1 (7-36) (GLP-1) is an endogen-
ous incretin hormone that modulates insulin-mediated
effects on glucose uptake and metabolism [1-3]. GLP-1
receptors are found in the heart, and several lines of evi-
dence suggest GLP-1 may have cardioprotective benefits
[4]. Therapeutic use of GLP-1 is limited by its rapid
degradation by dipeptidyl peptidase-4 (DPP-4). Exena-
tide, a synthetic version of the 39-amino acid peptide
exendin-4 not susceptible to cleavage by DPP-4, was ori-
ginally isolated from the salivary secretions of the Gila
monster lizard and shares several glucoregulatory prop-
erties with GLP-1 [5,6]. AC3174 ([Leu
14]exendin-4) is
an analog of exenatide with a single amino acid substi-
tution that has similar glucoregulatory properties to
both GLP-1 and exenatide [7]. Accumulating evidence
from both animal and human studies suggests GLP-1
receptor agonists can improve insulin sensitivity and
activate c-AMP mediated signaling pathways in cardiac
muscle cells [8-11].
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of whole-body insulin resistance with chronic heart fail-
ure (CHF) [12,13], suggesting an important role of insu-
lin resistance and/or altered glucose homeostasis in the
pathophysiology of CHF. Since the failing heart utilizes
glucose rather than free fatty acids as an energy source
[14,15], treatment with GLP-1 or exenatide may
improve both cardiac glucose metabolism and cardiac
function in CHF [16]. Additionally, acute treatment with
GLP-1 or exenatide has shown cardioprotective effects
i ns e v e r a la n i m a lm o d e l so fi s c h e m i aa n dp e r f u s i o n
injury [16-20], and recent data has reported that exena-
tide significantly reduces intimal hyperplasia in insulin
resistant animals independent of exenatide-associated
weight loss [21]. Further, in pilot studies continuous
infusion of GLP-1 improved cardiac function in patients
with myocardial infarction (MI), improved left ventricu-
lar (LV) function in patients with CHF, and was benefi-
cial in patients with type 2 diabetes with CHF [22-24].
However, no response was observed with acute GLP-1
infusion in patients with established cardiac disease [25].
The purpose of the present study was to determine
whether chronic treatment with GLP-1 or the exenatide
analog AC3174 has cardioprotective effects in a rat
model of MI-induced CHF, to identify specific aspects
of cardiac and metabolic function affected by GLP-1 or
AC3174, and to evaluate some potential mechanisms for
any observed effects.
Materials and methods
Induction of myocardial infarction
All experiments were performed in accordance with the
protocols and guidelines approved by the Institutional
Animal Care Committee and the NIH guide for the
Care and Use of Laboratory Animals. MI was induced
in male Sprague-Dawley rats (200-225 g) by the supplier
(Charles River Laboratories, Wilmington, MA) using a
previously described procedure [26]. Briefly, the left
anterior descending coronary artery was ligated with a
silk suture after an incision in the fourth intercostal
space under anesthesia (2% Isoflurane). The same surgi-
cal procedure was also performed on a group of rats
(sham-operated) except that the suture around the cor-
onary artery was not ligated. The wound was then
closed with metal clips, and the rats were allowed to
recover for one week before being shipped. Two weeks
after MI, rats with an LV infarct size between 20% and
45%, as estimated by echocardiograph at the authors’
facility, based on LV chamber kinetic movement [27].
These rats were then randomly assigned to treatment
groups and alzet pumps were implanted. Randomized
rats were infused subcutaneously with 2.5 pmol/kg/min
GLP-1 (GLPL, n = 11), 25 pmol/kg/min GLP-1 (GLPH,
n = 12), 1.7 pmol/kg/min AC3174 (3174L, n = 13),
5 pmol/kg/min AC3174 (3174H, n = 7), or vehicle (25%
DMSO + 75% H2O, control n = 13-16, sham n = 10) via
osmotic Alzet pumps (Durect Corp, Cupertino, CA) for
11 weeks. AC3174 and GLP-1 doses were selected to
provide equivalent plasma exposure [28]. Echocardiogra-
p h yw a sp e r f o r m e da t0 ,1 ,5 ,7 ,a n d1 1w e e k so ft r e a t -
ment (2, 3, 7, 9, and 13 weeks post-MI). At 10 weeks of
treatment (12 weeks post-MI), MI rats were subjected
to a treadmill test. During the last week of treatment,
blood samples for fasting plasma insulin and glucose
levels were collected before terminal hemodynamic mea-
surements were recorded.
Echocardiography
Echocardiograms were recorded under light anesthesia
(50 mg/kg ketamine hydrochloride plus 10 mg/kg xyla-
zine intraperitoneally) using a Hewlett-Packard 5500
system equipped with S12 (5-12 MHz) phased-array and
L15 (7-15 MHz) linear transducers. Transthoracic Dop-
pler echocardiography was performed as previously
described [29]. Briefly, short-axis images were obtained
at the papillary muscle level and 2 D guided M-mode
tracings were recorded at a speed of 150 mm/s. Anterior
and posterior end-diastolic wall thickness and LV inter-
nal dimensions were measured and % fractional shorten-
ing (FS%) was calculated. Left atrial (LA) volume, LV
end-diastolic volume (LVEDV), LV end-systolic volume
(LVESV), LV ejection fraction (LVEF), LV end-diastolic
dimension (LVEDD), and LV end-systolic dimension
(LVESD) were measured and calculated from apical
views [30,31].
Pulsed-wave Doppler spectra of mitral inflow were
obtained from the apical 4-chamber view. The peak
velocities of early (E) and late (A) filling waves, and E
wave deceleration rate were measured. LV diastolic fill-
ing was assessed by E/A ratio. Compliance was assessed
by E wave deceleration rate. Aortic velocity time integral
(VTI) and LV outflow track diameter were determined,
then stroke volume (SV) and cardiac output (CO) were
calculated according to the formula: CO = Aortic VTI ×
[π(LV outflow diameter/2)
2] × heart rate [32]. Images
were digitally acquired and stored for offline analysis by
a trained sonographer blinded to the study groups.
Exercise performance
Immediately before the treadmill test at 12 weeks post-
MI (10 weeks of treatment), baseline plasma lactate
levels were measured via tail vein puncture in conscious
rats fasted for 5 hours. At the time of the treadmill test,
2 rats were simultaneously placed on a 2-track treadmill
(Columbus Instruments, Columbus, OH) at a constant
5% grade enclosed by a metabolic chamber (Oxy-
max Deluxe, Columbus Instruments) through which
airflow was maintained at a constant flow rate. Basal
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minutes. The treadmill was then started at a velocity of
8 m/min for 3 minutes, followed by 12 m/min for 3
minutes, and then maintained at 18 m/min until rats
reached exhaustion. The endpoint for the treadmill test
was determined by a rat’s inability to maintain the pace
of the treadmill and remain on the electric shock grid
for over 6 seconds. Exercise capacity (EC) was calculated
as EC (kgm) = body weight (kg) × degree of grade ×
running distance. Oxygen consumption (VO2) was mea-
sured as described [32]. Plasma lactate was again mea-
sured one minute after the treadmill test.
Hemodynamics
Hemodynamic measurements were obtained under
anesthesia (2% isofluorane) at 13 weeks post-MI (11
weeks of treatment). A 2F micromanometer-tipped
transducer (Millar Instruments, Houston, TX) connected
to a PowerLab (8/30) system (ADInstruments, Colorado
Springs, CO) was inserted into the right carotid artery
to record systolic and diastolic blood pressure. The pres-
sure transducer was then advanced into the LV to mea-
sure LV systolic (LVSP) and end-diastolic (LVEDP)
pressures, the first derivative of LV pressure over time
(± dp/dt) and heart rate (HR).
Biochemical determinations
Plasma glucose and insulin levels were monitored after
an overnight fast at 13 weeks post-MI. Blood samples
(20 μl) were collected from a tail vein. Glucose and
insulin were measured using an Elite glucometer (Bay,
Elkhart, Indiana) and Ultrasensitive rat insulin ELISA kit
(Crystal Chem Inc, Chicago, Illinois), respectively. Base-
line fasting plasma insulin and glucose were utilized to
calculate the homeostasis model assessment (HOMA) of
insulin sensitivity. The estimate of insulin resistance
from the HOMA score was calculated as described by
Matthews et al [33].
Body composition analysis and histopathological
examination
Body weights of conscious rats were monitored weekly.
After completion of hemodynamic measurements, rats
were deeply anesthetized with 5% isoflurane. Lean and
fat mass were measured by quantitative magnetic reso-
nance (QMR) (EchoMRI; Echo Medical System, Huston,
TX) as described by Tinsley et al [34]. After QMR mea-
surement, rats were sacrificed under anesthesia and
hearts were excised. The atria were trimmed from the
ventricles, then the right ventricle, left ventricle, and
lung were separated and weighed. LV tissues were
immersion-fixed in 10% buffered formalin. Each heart
was cut in cross section at four levels from apex to base
and prepared for routine histological analysis. The
infarct portion of the LV was measured as previously
described [35].
Immunoblot analysis
Cardiac ventricular tissue of post-MI CHF rats from
control, GLPH and 3174H treated groups were homoge-
nized in lysis buffer and homogenized tissue extracts
were run on Bio Criterion XT Precast Gels and trans-
ferred to PVDF membranes (all from BioRad, Hercules,
CA). The membrane was immunoblotted with antibo-
dies directed against AKT2, cardiac sarcoplasmic reticu-
lum Ca
2+ ATPase (SERCA2), eNOS, glucose
transporters (GLUT 1 and GLUT 4), GAPDH, or PI3-
kinase-beta, and an HRP conjugate for the secondary
antibody (all antibodies from Abcam, Cambridge, MA).
Membranes were developed using SuperSignal West
Dura Substrate (Pierce, Rockford, IL), and assessed on
an Alpha Imager using chemifluorescence. AlphaEase
FC software version 1.4.0 was used for quantification.
Results were obtained in integrated density value units
per 10 μg total protein.
Purified plasma membranes (PM) and cytosolic (Cyt)
fractions were prepared using density gradient centrifu-
gation as previously described [36]. Translocation of
GLUT-1 and GLUT-4 was analyzed by assessing the
protein contents in the PM preparations expressed as
percentage of total protein expression in the PM and
Cyt fractions [37].
Statistics
Two-way repeated measures ANOVA followed by Bon-
ferroni multiple comparison tests were used to test
group differences in LV function and remodeling
over time. When a significant interaction was found (p
<0.05), differences between groups were analyzed for
each time point. Treadmill test data, body composition,
western blot, and hemodynamic measurements were
analyzed by one-way ANOVA followed by Bonferroni
multiple comparison or nonparametric Kruskal-Wallis
test followed by Dunnett’s multiple comparison. Within-
group comparisons of baseline and Peak VO2, lactate
and glucose data were analyzed by Student’sp a i r e d
t test. Time to death due to CHF was evaluated using
Kaplan-Meier survival curves. A log-rank trend test for
both GLP-1 and AC3174 was performed to evaluate
dose-response trend between control, low, and high
doses. The trend analysis was performed using equally-
spaced weights with no adjustment made for multiple
comparisons. Results are shown as mean ± SEM.
Results
General characteristics of rats with CHF
Post-MI vehicle control rats showed evidence of CHF,
including the development of LV dilatation, and LV
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Echocardiographic studies showed progressive differ-
ences in LV geometry between vehicle control
(infarcted) and sham-operated rats. Post-MI rats had
significant LV dilatation 2 weeks after ligation. During
the following 11 weeks, there was continued LV cham-
ber enlargement in the vehicle control group. The pro-
minent increase in cavity dimensions in the infarcted
hearts resulted in a significant decrease in relative wall
thickness (anterior wall/posterior wall thickness) com-
pared with vehicle control rats [31]. Hemodynamic
abnormalities were characteristic of rats with CHF. Spe-
cifically, vehicle control rats showed significantly
depressed LV ± dp/dt and elevated LVEDP (Table 2),
while cardiac output/body weight was decreased by 19%
(p <0.01) compared with sham-operated rats at 13
weeks post-MI. Control rats at 13 weeks post-MI exhib-
ited hyperglycemia and insulin resistance compared with
vehicle sham animals (Figure 2). Thus, the post-MI rats
we studied represented a homogenous group with
characteristics predisposing them to pathologic LV
remodeling and CHF.
Echocardiographic characteristics of infarcted rat hearts
prior to treatment
In all randomized post-MI rats at baseline, LV systolic
function (LVEF, CO/B.W, FS%) was depressed and LV
chamber size (LVESD, LVEDD, LVESV and LVEDV)
increased compared with sham-operated rats (Figure 1;
Table 1). LV diastolic dysfunction was present in post-
MI rats, as assessed by pulse-wave Doppler recordings
of mitral flow, compared with sham-operated rats.
Increased E/A ratio and E wave deceleration rate, char-
acteristics of LV diastolic dysfunction in failing hearts,
was observed in all randomized MI rats compared with
sham-operated rats. Left atrial volume was also
increased (Figure 1). Prior to treatment with a GLP-1R
agonist, there were no significant differences in LV or
LA chamber size, or systolic or diastolic function among
the randomized post-MI rats.
Table 1 Echocardiographic data in post-MI rats
Timepoint Sham Operated
(N = 10)
Vehicle Control
(N = 13)
GLPL
(N = 11)
GLPH
(N = 11)
3174L
(N = 11)
3174H
(N = 7)
LVEDD (cm) Baseline 0.63 ± 0.01 0.93 ± 0.02* 0.89 ± 0.01* 0.88 ± 0.02* 0.86 ± 0.02* 0.85 ± 0.04*
End of Study 0.82 ± 0.01† 1.16 ± 0.02 1.04 ± 0.03† 1.03 ± 0.03† 1.07 ± 0.03† 0.98 ± 0.05†
LVESD (cm) Baseline 0.34 ± 0.01 0.77 ± 0.02* 0.73 ± 0.02* 0.71 ± 0.02* 0.70 ± 0.03* 0.70 ± 0.03*
End of Study 0.05 ± 0.01† 0.99 ± 0.03 0.85 ± 0.03† 0.82 ± 0.04† 0.89 ± 0.04 0.73 ± 0.06†
FS (%) Baseline 46 ± 2 17 ± 1* 18 ± 1* 19 ± 1* 18 ± 2* 18 ± 1*
End of Study 39 ± 1† 16 ± 1 20 ± 2 21 ± 2† 18 ± 1† 26 ± 3†
LVEDV (ml) Baseline 0.26 ± 0.02 0.59 ± 0.03* 0.52 ± 0.03* 0.53 ± 0.03* 0.56 ± 0.04* 0.52 ± 0.05*
End of Study 0.51 ± 0.02† 0.99 ± 0.05 0.83 ± 0.05† 0.72 ± 0.04† 0.77 ± 0.02† 0.73 ± 0.06†
LVESV (ml) Baseline 0.08 ± 0.01 0.37 ± 0.03* 0.32 ± 0.02* 0.33 ± 0.03* 0.34 ± 0.03* 0.33 ± 0.04*
End of Study 0.17 ± 0.01† 0.69 ± 0.04 0.52 ± 0.05† 0.42 ± 0.04† 0.47 ± 0.03† 0.44 ± 0.07†
LVEF (%) Baseline 69 ± 2 37 ± 2* 39 ± 1* 39 ± 2* 39 ± 3* 38 ± 3*
End of Study 66 ± 2† 31 ± 2 38 ± 3† 43 ± 3† 39 ± 3† 41 ± 5†
E Wave (cm/s) End of Study 0.89 ± 0.04 1.05 ± 0.50 0.93 ± 0.07 0.89 ± 0.05 1.02 ± 0.06 0.95 ± 0.04
A Wave (cm/s) End of Study 0.48 ± 0.06† 0.36 ± 0.06 0.42 ± 0.04† 0.43 ± 0.04† 0.45 ± 0.05† 0.44 ± 0.05†
E/A Ratio Baseline 1.6 ± 0.1 3.4 ± 0.5* 4.4 ± 0.8* 3.9 ± 0.6* 3.9 ± 0.8* 4.0 ± 0.4*
End of Study 2.0 ± 0.2† 4.5 ± 0.8 2.5 ± 0.4† 2.5 ± 0.4† 2.9 ± 0.6† 2.5 ± 0.5†
E Wave Deceleration (m/s
2) Baseline 13.8 ± 0.6 18.5 ± 1.2* 19.2 ± 1.8* 17.7 ± 0.8* 17.9 ± 1.4* 18.0 ± 0.6*
End of Study 16 ± 1† 25 ± 3 18 ± 3† 16 ± 2† 19 ± 3 17 ± 2†
LV Wall Thinning Ratio Baseline 1.06 ± 0.02 0.87 ± 0.02* 0.89 ± 0.03* 0.89 ± 0.02* 0.89 ± 0.03* 0.88 ± 0.03*
End of Study 1.08 ± 0.03† 0.76 ± 0.02 0.84 ± 0.04 0.88 ± 0.04† 0.79 ± 0.04 0.93 ± 0.06†
Heart Rate (beats/min) Baseline 273 ± 5 270 ± 7 266 ± 10 292 ± 10 284 ± 7 261 ± 2
End of Study 257 ± 15 243 ± 7 269 ± 8 262 ± 6 246 ± 9 258 ± 7
CO/Body Wt (ml/min/g) End of Study 0.21 ± 0.01† 0.17 ± 0.01 0.20 ± 0.01† 0.20 ± 0.01† 0.19 ± 0.01† 0.22 ± 0.01†
The LV wall thinning ratio is the ratio of the anterior wall thickness to the posterior wall thickness. Mean ± SEM. *P < 0.05 versus sham-operated group at
baseline. †P < 0.05 versus vehicle-treated group at the end of the study. LV, left ventricular; EDD, end-diastolic dimension; ESD, end-systolic dimension; FS,
fractional shortening; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; E, early filling wave; A, late filling wave; E/A ratio, Doppler ratio of
early to late transmitral flow velocity; Wt, weight; CO, cardiac output.
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treatment
Control rats
During the 11-week observation period, LV systolic and
diastolic function progressively decreased in control rats
compared with sham-operated rats (Figure 1, Tables 1,
2). Specifically, in the vehicle control rats at 13 weeks
post-MI, LVEF decreased 53% (P < 0.05), FS% decreased
60% (P < 0.05), E/A ratio increased 120% (P < 0.05), and
LVEDP increased by 97% (p <0.05) compared with the
sham-operated rats.
Treated rats
Treatment with GLP-1 and AC3174 significantly
improved both diastolic function (E/A ratio, LVEDP,
Figure 1 Effect of chronic treatment with GLP-1 or AC3174 on cardiac function and survival. (A) Left ventricular ejection fraction (LVEF). At
weeks 3 and 5 post-MI, 3174H LVEF was significantly less than GLPL LVEF (p < 0.05). At week 3 post-MI, 3174H LVEF was significantly less than
3174L LVEF (p < 0.05). (B) Doppler ratio for early (E) to late (A) transmitral flow velocity (E/A ratio). (C) Left ventricular end-diastolic dimension
(LVEDD). (D) Left ventricular end-systolic dimension (LVESD). (E) Left atrial volume. (F) Kaplan-Meier survival curves. The number of chronic heart
failure (CHF) related deaths (from 2 weeks post-MI) and the total number in each group were sham 0/10; control 4/16; GLPL 1/12; GLPH 0/12;
3174L 0/13 and 3174H 0/7. *p < 0.05 versus vehicle-treated control group.
Table 2 Hemodynamic changes at the end of the study
Sham Operated
(N = 10)
Vehicle Control
(N = 12)
GLPL
(N = 11)
GLPH
(N = 12)
3174L
(N = 13)
3174H
(N = 7)
Heart Rate (beats/min) 252 ± 13 268 ± 21 294 ± 20 295 ± 13 256 ± 16 312 ± 15
Mean BP (mmHg) 83 ± 5 80 ± 8 87 ± 7 84 ± 4 72 ± 2 83 ± 4
LVEDP (mmHg) 10.6 ± 0.9* 20.9 ± 1.4 12.7 ± 0.01* 12.3 ± 1.6* 14.4 ± 1.4* 13.9 ± 1.7*
+ dp/dt (mmHg/s) 5789 ± 430* 4426 ± 541 6157 ± 654* 6044 ± 284* 5234 ± 372 5948 ± 488*
-dp/dt (mmHg/s) 5826 ± 655* 3731 ± 564 5450 ± 652* 5582 ± 465* 4424 ± 386 5798 ± 592*
Mean ± SEM. *P < 0.05 versus vehicle-treated group. BP, blood pressure; dp/dt, first derivative of left ventricular pressure over time.
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FS%, CO/BW) compared with the vehicle control group
over time, although cardiac function did not reach that of
sham-operated animals for most parameters (Figure 1,
Tables 1, 2). Specifically, LVEDP was significantly reduced
by 41% in the GLPH group and 33% in the 3174H group
compared with the vehicle control group. Conversely, LVEF
was significantly increased by 39% in the GLPH group and
33% in the 3174H group. In the GLPH and 3174H groups,
LV contractility (± dp/dt) was also significantly improved
(P < 0.05), while HR and BP were not affected.
Cardiac geometry
Control rats
LV chamber size in the vehicle control group increased
progressively compared with sham-operated rats during
the 11-week observation period, while LV wall thickness
ratio was significantly reduced (P < 0.05, Figure 1,
Tables 1 and 2). LVEDD was significantly increased by
42%, LVESD was significantly increased by 97%, LVEDV
was significantly increased by 95%, and LVESV were
significantly increased by 300% in vehicle control post-
MI rats 13 weeks post-MI. In vehicle control rats, LV
wall thickness ratio was reduced by 30% and LA volume
was increased by 79% compared with sham-operated
rats 13 weeks post MI.
Treated rats
The progression of LV chamber dilatation and thinning
of the LV wall was dose-dependently attenuated in both
GLP-1 and AC3174 treatment groups (Figure 1, Tables
1 and 2). Compared with the vehicle control group,
LVEDV was significantly reduced by 26% (P < 0.05) and
LVESV was significantly reduced by 36% (P < 0.05) in
the 3174H group. LVEDV was significantly reduced by
27% (P < 0.05) and LVESV was significantly reduced by
39% (P < 0.05) in the GLPH group. Treatment with
GLP-1 or AC3174 dose-dependently attenuated the
increase of LA volume observed in the vehicle control
rats.
Insulin sensitivity
Control rats
Fasting plasma glucose and insulin levels were signifi-
cantly higher in the vehicle control group compared
with the sham-operated group at 13 weeks post-MI (P <
0.05, Figure 2). As a result, insulin resistance as assessed
by HOMA, was 2 fold higher than in the sham-operated
group.
Treated rats
After 11 weeks of treatment, GLP-1 or AC3174 signifi-
cantly reduced plasma glucose, insulin and HOMA
compared with the vehicle-treated/control group (P <
0.05, Figure 2), indicating that insulin sensitivity was
improved in all treated groups.
Treadmill test, Peak VO2, and plasma lactate levels
Control rats
Basal VO2 was comparable, and peak VO2 (PVO2)w a s
significantly higher than basal VO2 among all groups
(P < 0.05, Table 3). Compared with sham-operated rats,
running distance was significantly decreased by 63%
(P < 0.05) and EC was significantly decreased by 63%
(P < 0.05) in vehicle treated post-MI rats with CHF.
Figure 2 Effects of GLP-1 and AC3174 on fasting glucose,
insulin levels and HOMA 13 weeks post-MI. * p < 0.05, † p<
0.01, ‡ p < 0.001 versus vehicle control group. Results are mean +
SEM.
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Treatment with GLP-1 or AC3174 significantly improved
running distance and EC in rats with CHF compared
with vehicle control animals (P < 0.05, Table 3). Com-
pared with the vehicle control group, PVO2 was not sig-
nificantly changed in sham-operated and GLP-1 or
AC3174 treated groups. As a result, the EC/PVO2 ratio
was significantly higher in all groups compared with the
vehicle control group (P < 0.05). PVO2 in the 3174H
group was significantly lower than in the 3174L group (P
<0 . 0 5 ) .O fn o t e ,t h eE C / P V O 2 ratio in the 3174H group
was 1.9 fold-higher than the control group.
Immediately after exercise, peak plasma lactate level
was significantly higher than basal levels in each group
(P < 0.05). Interestingly, basal plasma lactate levels in
the vehicle control group were significantly higher than
in the sham-operated and GLP-1 or AC3174-treated
groups. Although peak plasma lactate levels were com-
parable among all groups, the EC/lactate ratio was sig-
nificantly higher in sham-operated and GLP-1 or
AC3174 treated groups (P < 0.05), indicating a higher
efficiency of glucose utilization.
Survival
Over the 13-week post-MI period, 25% of the vehicle
control group (4 out of 16 rats) died with signs of CHF
(e.g., respiratory distress, and general fatigue: defined as
a fast respiratory rate and a reluctance to move.). Eight
p e r c e n to ft h eG L P Lg r o u p( 1o u to f1 2r a t s )d i e dw i t h
signs of CHF. There were no deaths in the sham-oper-
ated, GLPH, 3174L, or 3174H groups. As shown in Fig-
ure 1F, the Kaplan-Meier survival curves indicate
increased mortality for the vehicle control MI group
compared with the other treatment groups. Trend tests
for GLP-1 (p = 0.05) and AC3174 (p < 0.05) showed
marginally significant dose responses. There was no sig-
nificant difference between the GLP-1 and AC3174
treatment groups. The death rate for all rats treated
with a GLP-1R agonist was 2% (1 death out of 44 rats).
Body composition, heart, lung weight and infarct size
Progressive body weight loss was observed in the
AC3174-treated groups during the 11-week treatment
period. Weight loss was associated with a dose-depen-
dent reduction in fat mass accompanied by preservation
of lean body mass (Table 4). In the 3174H group, body
weight decreased 17%, fat mass decreased 45% and fluid
mass decreased 11% compared with the vehicle control
group. By contrast, there were no significant changes in
body weight and composition in the GLP-1 treatment
groups over the same time period. LV, RV, and lung
weights were generally significantly lower in sham, GLP-
1 and AC3174 groups compared with the vehicle con-
trol group (P < 0.05). Because body weight also
decreased in the GLP-1 and AC3174 groups, the ratios
of LV, RV, and lung to body weight did not reach signif-
icance for all doses of GLP-1 and AC3174, although
lung weight was reduced at the higher doses of both
agents. There was no significant change in infarct size
among any of the groups.
Effects of GLP-1 or AC3174 on myocardial GLUT4 and
GLUT1 translocation
Figure 3A shows a representative immunoblot of the
relative GLUT1 or GLUT4 distribution between the PM
and Cyt fractions in sham, vehicle, GLP1 H or 3174H
treated MI rats. Antibody binding specifically detected
GLUT1 and GLUT4 protein of average molecular mass
~50 kDa and ~45 kDa, respectively, matching the pre-
viously described molecular mass of these proteins [37].
Compared with the vehicle control group, treatment
with GLP-1 or AC3174 did not change the relative
GLUT4 content in the plasma membrane (60.0 ± 4.4%
and 61.4 ± 5.5% vs 55.3 ± 4.9%, respectively; Figure 3B).
Table 3 Metabolic response during the treadmill test at the end of the study
Sham Operated
(N = 10)
Vehicle Control
(N = 12)
GLPL
(N = 11)
GLPH
(N = 12)
3174L
(N = 13)
3174H
(N = 7)
Plasma Lactate (mM) Basal 1.7 ± 0.2* 2.7 ± 0.2 1.9 ± 0.2* 1.9 ± 0.2* 2.0 ± 0.2* 2.1 ± 0.1*
Peak 2.5 ± 0.2† 3.1 ± 0.4 2.7 ± 0.3† 3.1 ± 0.6† 3.7 ± 0.5† 3.2 ± 0.5†
VO2 (ml/kg/h) Basal 949 ± 67 1027 ± 84 1040 ± 110 1117 ± 108 1073 ± 77 872 ± 57
Peak 2022 ± 155† 1949 ± 290† 2334 ± 311† 2659 ± 329† 2554 ± 307† 1431 ± 155†#
EC (kg*m) 679 ± 127* 253 ± 52 452 ± 58* 547 ± 56* 535 ± 89* 562 ± 167*
EC/Peak Lactate Ratio 290 ± 54* 86 ± 18 200 ± 36* 234 ± 44* 163 ± 31* 203 ± 69*
EC/Peak VO2 Ratio 38.0 ± 7.2* 14.0 ± 3.2 23.4 ± 4.2 24.8 ± 4.3* 24.4 ± 5.4 40.4 ± 12.2*
Running Distance (m) 266 ± 50* 99 ± 21 177 ± 22 212 ± 21* 220 ± 36* 251 ± 82*
Mean ± SEM. *P < 0.05 versus vehicle-treated group. †P < 0.05 peak versus basal in same group. #P < 0.05 3174L versus 3174H group. VO2, oxygen consumption;
EC, exercise capacity.
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also unchanged by GLP-1 or AC3174 treatment (37.7 ±
2.9% or 34.8 ± 5.1% vs 41.8 ± 2.5%). These results sug-
gest that GLP-1 or AC3174 do not significantly affect
myocardial GLUT1 and GLUT4 translocation under the
present experimental conditions.
Effects of GLP-1 or AC3174 on cardiac protein expression
Immunoblot analysis of cardiac tissue did not demon-
strate any significant changes in expression of GLUT4,
AKT2, SERCA2a or PI3Kbeta with GLP-1 or AC3174
treatment (Figure 4), although trends towards decreased
GLUT1 and eNOS expression were noted.
Table 4 Whole body and selected organ composition at the end of the study
Sham Operated
(N = 10)
Vehicle Control
(N = 12)
GLPL
(N = 11)
GLPH
(N = 12)
3174L
(N = 13)
3174H
(N = 7)
Body Wt (g) 511 ± 16 522 ± 17 523 ± 14 518 ± 12 493 ± 10 435 ± 15*
Baseline Body Wt (g) 257 ± 7 272 ± 8 270 ± 7 276 ± 10 258 ± 5 258 ± 5
Fat Mass (g) 58 ± 6 47 ± 6 45 ± 6 51 ± 9 33 ± 3* 26 ± 5*
Lean Mass (g) 35 ± 1 38 ± 1 37 ± 2 35 ± 2 38 ± 2 34 ± 1
Fluid Mass (g) 323 ± 12 343 ± 9 329 ± 14 331 ± 15 332 ± 11 305 ± 9*
LV (g) 1.07 ± 0.06* 1.36 ± 0.10 1.26 ± 0.05 1.13 ± 0.03* 1.13 ± 0.05* 1.06 ± 0.04*
RV (g) 0.22 ± 0.01* 0.28 ± 0.02 0.22 ± 0.01* 0.23 ± 0.01* 0.24 ± 0.01* 0.20 ± 0.02*
Lung (g) 1.53 ± 0.05* 2.45 ± 0.05 1.94 ± 0.35 1.66 ± 0.13* 1.48 ± 0.03* 1.51 ± 0.07*
LV Wt/Body Wt (%) 0.21 ± 0.01* 0.26 ± 0.01 0.24 ± 0.01 0.22 ± 0.01* 0.23 ± 0.01* 0.24 ± 0.01
RV Wt/Body Wt (%) 0.04 ± 0.002* 0.05 ± 0.01 0.04 ± 0.002* 0.04 ± 0.002* 0.05 ± 0.002 0.05 ± 0.002
Lung Wt/Body Wt (%) 0.30 ± 0.01* 0.48 ± 0.10 0.37 ± 0.07 0.32 ± 0.02* 0.30 ± 0.01* 0.33 ± 0.01*
Infarct Size (%) 0±0 3 3±4 3 0±2 2 9±2 3 1±3 3 1±6
Mean ± SEM. *P < 0.05 versus vehicle-treated group. Wt, weight; LV, left ventricle; RV, right ventricle.
Figure 3 Effects of GLP-1 or AC3174 treatment on GLUT1 and GLUT4 translocation. MI rat hearts were obtained from the sham, vehicle
control, GLPH and 3174H treatment groups. (A) Representative Western blots of GLUT1 and GLUT4 in plasma membrane and cytoplasm. (B)
Quantitative analysis of GLUT4 proteins in plasma membrane. No significant changes with treatment compared to vehicle control were
observed. Results are mean + SEM. N = 3 per group.
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Overview
The present study demonstrates that 11 weeks of GLP-1
or AC3174 infusion to post-MI rats developing CHF
can significantly improve multiple clinically-relevant
parameters of cardiac function in a model of moderate,
stable, compensated heart failure. In comparison with
vehicle-treated rats, improvements were observed in
LVEF, fractional shortening, transmitral flow ratio,
E-wave velocity, cardiac wall-thinning ratio, LVEDP, dP/
dT, and cardiac output. Measured parameters of cardiac
morphology were also improved by GLP-1 or AC3174
infusion, including LV end systolic and end diastolic
diameter, and left atrial volume. In contrast, heart rate
and mean blood pressure in GLP-1R agonist-treated ani-
mals were not different from those of vehicle control
animals. Left ventricular infarct size was not affected by
GLP-1 or AC3174, and no differences in body weight-
adjusted measures of heart weight were observed. How-
ever, unadjusted LV and RV weights were decreased.
Furthermore, a statistically significant improvement in
survival was observed with GLP-1 and AC3174 treat-
ments at both low and high doses.
More detailed analyses of the physiological changes
resulting from either GLP-1 or AC3174 infusion indicate
that fluid balance, glucose metabolism, and respiratory
efficiency improved compared with vehicle control ani-
mals with CHF. Differences in fluid balance were evi-
denced by reductions in lung weight (adjusted for body
w e i g h t )a n df l u i dm a s sc o m p a r e dw i t hp o s t - M Iv e h i c l e
control animals. Improvements in glucose metabolism
were evidenced by reductions in plasma glucose, plasma
insulin, and insulin resistance. Improved exercise capa-
city in GLP-1 or AC3174-treated animals was associated
with reduced peak oxygen consumption during exercise
and lower basal lactate production, reflecting improved
respiratory efficiency. Running distances in post-MI rats
treated with GLP-1 or AC3174 were not significantly
different from that of sham-operated animals and were
double that of vehicle control animals with CHF.
Exploration of Possible Mechanisms
These studies did not identify the molecular mechan-
isms mediating the GLP-1 and AC3174 changes in phy-
siological function. No differences in translocation of
GLUT1 or GLUT4 to the plasma membrane were
observed between GLP-1 and AC3174-treated rats and
no statistically significant differences in expression of
these proteins were identified. This contrasts with the
results from chronically infarcted Wistar rat hearts
where myocardial GLUT4 protein levels were 28% lower
in infarcted hearts than in sham-operated hearts, and
insulin-stimulated glucose uptake was 42% lower [38].
No differences in the protein expression of AKT2,
SERCA2a, or PI3Kbeta were observed, and the observed
trend towards reduction in eNOS expression might be
expected to diminish cardiac function rather than
improve it. However, studies in normal primary human
coronary artery endothelial cells in vitro have demon-
strated a similar lack of overt exenatide effect on eNOS
and AKT2 protein expression on a background of
enhanced activation of both proteins [39]. Indeed,
endothelial cells had a substantial proliferative response
to exenatide treatment and this response was mediated
by activation of both the AKT2/eNOS and the PKA/
PI3K signal transduction pathways. Furthermore, activa-
tion of the GLP-1 receptor was required upstream for
stimulation of these pathways. Along the same lines of
inquiry, treatment of diabetic post-MI mice with the
DPP-4 inhibitor sitagliptin, which augments concentra-
tions of endogenous full-length GLP-1, reduced mortal-
ity and improved cardiac function [40].
Role of Glucose Metabolism in CVD
This study demonstrated the development of insulin
resistance and hyperglycemia in a MI-induced rat model
of CHF, supporting the similarity of this model system
with human CHF. Improvements in whole-body insulin
sensitivity and glycemic control are closely associated
with attenuation of cardiac insulin resistance and appear
to protect the heart in both patients and animals with
coronary heart disease [14,41]. Several animal studies
have shown that increasing glucose utilization not only
improves cardiac function, but also attenuates cardiac
remodeling during CHF [14,35,42]. Further, a role of
GLP-1 in cardioprotection is supported by the cardiac
phenotype of GLP-1R knockout mice where resting
heart rate is reduced, LV wall thickness is increased,
and LVEDP is elevated compare with wild-type mice
[43]. Although baseline hemodynamics are normal, after
the administration of insulin or epinephrine LV contrac-
tility and diastolic function also show impairment.
The close relationship between the metabolic syn-
drome and cardiovascular diseases, including CHF, is
well established [4,11-13,20,25,38]. In previous studies,
exenatide progressively reduced body weight in obese
animals and humans, and increased insulin sensitivity in
obese animals [6,44-47]. In the present study, the com-
bined actions of the exenatide analog AC3174 to reduce
body weight, fat mass, insulin resistance, cardiac remo-
deling, and improve glycemic control and cardiac func-
tion suggest the overall improvement in metabolic
status observed with AC3174 treatment may contribute
to its cardioprotective mechanisms. Further evidence
was provided by the decreased rates of mortality in
AC3174-treated MI rats compared with vehicle control
rats. In patients with CHF and diabetes, but not in
normoglycemic patients with CHF, a 5 week infusion of
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Page 9 of 14Figure 4 Effects of GLP-1 and AC3174 on expression of selected cardiac proteins. MI rat hearts were obtained from the sham, vehicle
control, GLPH and 3174H treatment groups. (A) Representative Western blots. (B) Quantitative analysis of cardiac protein expression showing no
significant change with treatment compared to vehicle control. Results are mean + SEM. N = 3 per group.
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However, cardiac function in both groups of patients
was significantly and comparably improved by GLP-1.
These results suggest that GLP-1 effects that are inde-
pendent of whole body metabolic improvements contri-
bute relatively more to GLP-1’s cardioprotective effects,
perhaps via direct myocardial actions.
In a global ischemia model in isolated rat hearts, GLP-1
treatment post-MI exhibited only a small tendency to
increase mechanical (inotropic) performance [48]. Rather,
GLP-1’s primary mechanism of action was cardioprotec-
tive in nature (39% reduction in infarct size) and mediated
through the GLP-1 receptor. In isolated mouse hearts,
GLP-1 increased functional recovery and cardiomyocyte
viability after ischemia-reperfusion injury [49]. In models
of MI (ischemia with or without reperfusion) and heart
failure, treatment with GLP-1 or exenatide treatment has
generally been associated with improvements in post-
ischemia cardiac function or infarct size. The most striking
results were observed in studies with longer follow-up
times. For example, in pigs treated for 2 days, exenatide
reduced infarct area 33%, prevented deterioration of systo-
lic and diastolic cardiac function, and decreased myocar-
dial stiffness 54% when assessed on the third day after
treatment initiation [19]. At the molecular level, AKT acti-
vation increased in concert with increased expression of
anti-apoptotic BCL-2 and decreased expression of pro-
apoptotic caspase 3. In a second example, 7 days of pre-
MI treatment with the GLP-1R agonist liraglutide reduced
mouse cardiac infarct size, while improving cardiac output
and survival [9]. Four weeks post-MI, measures of systolic
function (cardiac output, stroke volume) and mitral flow
velocities (E/A ratio) were significantly improved com-
pared with sham-operated mice, combined with reduced
LV dilatation. Furthermore, all these effects were indepen-
dent of liraglutide-induced weight loss. Ex vivo, liraglutide
prevented ischemia-reperfusion injury in isolated, perfused
mouse hearts and reduced apoptosis in neonatal mouse
cardiomyocytes. In normal healthy mice (without MI), lira-
glutide increased AKT activation, a response that was
absent in GLP-1R knockout mice. In the one study exam-
ining human patients with acute MI, 72-hours of GLP-1
infusion added to standard therapy was associated with
significantly improved LVEF (29% to 39% compared with
no change in the control group) and contractile function
(-21% in regional wall motion score index versus no
change in the control group) measured 6 to 12 hours after
infusion [22]. Moreover, in pigs and dogs GLP-1 improved
myocardial glucose-uptake and metabolism [50,51].
Clinical Evidence
The ability of exenatide to reduce blood pressure in
humans may contribute to the peptide’s potential to
play a cardioprotective role. In an open-label, 82-week
study in patients with type 2 diabetes, exenatide reduced
mean diastolic blood pressure and improved lipid pro-
files [44]. In a 24-week, clinical trial in patients with
type 2 diabetes, exenatide reduced mean systolic and
diastolic blood pressure in contrast to non-significant
changes in the placebo arm [47]. The blood pressure
effects of exenatide treatment lasting at least 6 months
was also examined in pooled data from 6 trials including
2,171 subjects [52]. Exenatide was associated with signif-
icantly decreased systolic BP compared with placebo or
insulin in patients with elevated BP at baseline, with the
greatest effects observed in subjects with baseline systo-
lic BP ≥130 mmHg.
In another study, 12 weeks of exenatide treatment in
patients with type 2 diabetes was associated with a trend
towards lower 24-hr, daytime, and nighttime systolic
blood pressure, but had no clinically meaningful effect
on heart rate, compared with placebo [53]. Further,
using a well-established risk-assessment model, Sullivan
et al. [54] projected substantial reductions in cardiovas-
cular death rates and fewer cardiovascular events over
30 years in patients with diabetes treated with the GLP-
1R agonist, liraglutide.
Exercise intolerance is a hallmark symptom of CHF
regardless of disease etiology, and is closely related to
increased insulin resistance [55]. Agents that stimulate
glucose oxidation (directly or indirectly) improve exer-
cise capacity in humans [56-58]. In the present study, a
reduction in basal plasma lactate and an increase in the
ratio of exercise capacity to the lactate peak during exer-
cise was observed with GLP-1 or AC3174 treatment, in
parallel with increased insulin sensitivity. These data
suggest whole body glucose utilization was improved in
all treatment groups. Thus, it is possible that normaliza-
tion of hyperglycemia and improvement in insulin sensi-
tivity may have contributed to the enhancement of
exercise performance, in addition to the benefits of
improved cardiac function and remodeling. However,
whether or not the improvements in insulin sensitivity
associated with chronic GLP-1 or AC3174 treatment
directly contributed to the cardioprotective effects of
these peptides remains to be determined. Regarding the
significantly lower VO2 levels observed in the 3174H
group, reduced food intake/body weight may have con-
tributed to this result. Previous studies have shown that
equivalent doses of exenatide lower food intake in diet
induced obese rats [46]. However, the mechanism of
action of AC3174 to change VO2 is not clear and is
likely to be multifactorial.
Implications of GLP-R Activation for Survival after MI
Survival increased with GLP-1 or AC3174 treatment in
the MI-induced CHF rat model. Although attenuat-
ion of insulin resistance by GLP-1 or AC3174 may
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extra-cardiac actions such as vasodilatation, renoprotec-
tion, and reduction of apoptosis [2,59-61] may have also
contributed to the reduction in mortality. Of mention,
insulin sensitizers such as peroxisome proliferators-
activated receptor g (PPARg) activators (e.g., thiazolidi-
nediones) have cardioprotective effects similar to GLP-1.
However, PPARg activators are contraindicated in CHF
due to their propensity to increase the incidence of fluid
retention and edema in humans [62], and increase mor-
tality in rats with MI-induced CHF [63].
While the mechanisms of the observed cardioprotective
effects remain unclear, several likely mechanisms were
explored. In a previous study of isolated perfused rat
hearts subjected to ischemia and reperfusion, acute treat-
ment with high concentrations of GLP-1 enhanced recov-
ery of cardiac function by improving myocardial glucose
uptake and translocation of the glucose transporters,
GLUT-1 and GLUT-4, during reperfusion [20]. Although
the mechanism of translocation remains elusive, it appears
the AKT-2 downstream signal transduction pathway con-
tributes to the translocation of GLUT-4 [64]. In the pre-
sent study, long term treatment with GLP-1 or AC3174
did not significantly alter myocardial GLUT1 or GLUT4
translocation. These data suggest the observed cardiopro-
tective effects may occur, at least in part, independent of
specific cardiac metabolic improvements.
While GLP-1 and the exenatide analogue AC3174
exhibit comparable binding potency at the GLP-1 recep-
tor [7], in this study AC3174 exhibited several distinct
pharmacodynamic actions compared with GLP-1. For
instance, treatment with AC3174 resulted in significant
weight loss mediated by selective loss of body fat.
Furthermore, the highest dose of AC3174 tested was
associated with a relatively low PVO2. This could be due
to relatively more potent and sustained inhibitory effects
of exenatide on food intake and energy expenditure
than observed with GLP-1 [65]. However, the cardiopro-
tective effects of the GLP-1R agonist liraglutide in a
mouse MI model were found to be independent of
weight reduction [9].
In an isolated rat heart model of MI, administration of
GLP-1 during the first 15 minutes post-ischemia reper-
fusion reduced infarct size through a GLP-1 receptor-
mediated pathway, but had no inotropic effects
(mechanical performance) [48]. In contrast, administra-
tion of the primary GLP-1 metabolite GLP-1(9-36) had
no effect on infarct size, but did have a strong negative
inotropic effect. Because GLP-1(9-36) has little or no
binding affinity for the known GLP-1R, these data sug-
gest the involvement of GLP-1R-independent effects on
cardiac function post-MI. A more recent exploration of
this hypothesis found that isolated mouse hearts rapidly
convert infused GLP-1 to GLP-1(9-36) [66]. After
ischemia-reperfusion injury of isolated mouse hearts,
administration of GLP-1(9-36) or exenatide improved
functional recovery, reduced infarct size, improved car-
diomyocyte viability, reduced lactate dehydrogenase
release and decreased caspase-3 activation. Counter to
expectations, the cardioprotective actions of GLP-1
(9-36) were blocked by an antagonist of GLP-1R bind-
ing, yet preserved in cardiomyocytes from GLP-1R
knockout mice. Overall, these data lend further support
to a cardio-sparing signal transduction pathway distinct
from that associated with the GLP-1 receptor.
Limitations
One possible limitation of this study is that standard
treatments for MI, e.g. ACE-inhibitors, were not co-
administered with GLP-1 or AC3174. However, in a
recent publication [60], the ACE inhibitor captopril had
additive effects with AC3174 in reducing cardiac left
ventricular mass and improving renal morphology in a
rat model of hypertension characterized by profound
hypertension, cardiac hypertrophy, insulin resistance,
renal pathology, and early-onset mortality. AC3174 plus
captopril lengthened survival and had anti-hypertensive,
insulin-sensitizing, and renoprotective effects. Another
possible limitation is that levels of catecholamines, corti-
sol, glucagon, free fatty acids, renin, and aldosterone
were not measured in the MI rat model. Levels of these
compounds can increase in heart failure patients and it
is possible similar changes may have influenced the phy-
siological responses to AC3174 or GLP-1 in the rat
model.
Conclusions
GLP-1 and the exenatide analog, AC3174, each indepen-
dently demonstrated cardioprotective effects after long-
term treatment in rats with MI-induced CHF, a model
of moderate, stable, compensated heart failure. Overall,
the cardioprotective benefits of GLP-1 and AC3174
appeared similar, suggesting that in this model, the
major GLP-1 metabolite (GLP-1 9-36) is not necessary
for mediating these specific improvements. Therefore,
based on the findings from the present study and the
accumulating body of clinical evidence with exenatide,
therapy with GLP-1 receptor agonists may represent a
promising approach for the treatment of patients with
CHF or cardiovascular disease associated with type 2
diabetes, supporting the need for further research in this
field.
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